Literature DB >> 10412731

Apolipoprotein E polymorphism and renal disease.

H Oda1, N Yorioka, C Ueda, S Kushihata, M Yamakido.   

Abstract

BACKGROUND: Lipid abnormalities are frequently found in end-stage renal disease (ESRD), and abnormal lipid metabolism may contribute to the progression of renal disease. Previous investigators have reported that apolipoprotein E (apoE) has an important role in lipoprotein metabolism and that the process of lipoprotein catabolism varies according to the apoE phenotype. In addition, the relative frequency of the apoE alleles is different among the races. In this study, we investigated the allele frequency of apoE phenotypes and evaluated the impact of apoE polymorphism on lipid profile in Japanese patients with renal disease.
METHODS: ApoE phenotypes were determined using isoelectric focusing and Western blotting in 592 Japanese patients with renal disease [86 out of 107 patients with glomerulonephritis had proteinuria of not less than 0.25 g per 24 hr and 485 with ESRD; 448 were on hemodialysis (HD), and 37 were on continuous ambulatory peritoneal dialysis (CAPD)]. The allele frequency and apoE phenotype distribution were estimated by the gene-counting method. Serum lipid parameters related to lipid metabolism were measured after at least a 12-hour fast.
RESULTS: The allele frequency of the three major apoE phenotypes (apoE2, apoE3, and apoE4) in 107 glomerulonephritis patients (epsilon 2; 0.037, epsilon 3; 0.860, epsilon 4; 0.103) was almost identical to that in the normal control population (epsilon 2; 0.036, epsilon 3; 0.848, epsilon 4; 0.115). However, 86 glomerulonephritis patients with proteinuria had higher allele frequency of apoE2 (epsilon 2; 0.052, P < 0.01) and apoE4 (epsilon 4; 0.140, P < 0.001) and lower allele frequency of apoE3 (epsilon 3; 0.808, P < 0.001) than the controls. Furthermore, ESRD patients had higher allele frequency of apoE2 (epsilon 2; 0.058, P < 0.01) and lower allele frequency of apoE4 (epsilon 4; 0.091, P < 0.05) than the controls. Higher prevalence of nephrotic syndrome was found in proteinuric glomerulonephritis patients with apoE2. The impact of apoE polymorphism on serum lipid profile in patients with glomerulonephritis, HD, and CAPD was different from that generally expected.
CONCLUSIONS: The higher frequency of apoE2 in ESRD patients suggests that apoE2 is a possible genetic predisposition to ESRD in a Japanese population. The impact of apoE2 and apoE4 on lipid profile in patients with renal disease was unique and different from that in the normal population.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10412731     DOI: 10.1046/j.1523-1755.1999.07107.x

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  9 in total

1.  Apolipoprotein E polymorphism in hemodialyzed patients and healthy controls.

Authors:  Jaroslav A Hubacek; Silvie Bloudickova; Ruzena Kubinova; Hynek Pikhart; Ondrej Viklicky; Martin Bobak
Journal:  Biochem Genet       Date:  2009-06-30       Impact factor: 1.890

2.  Apolipoprotein E polymorphism and clinical course in childhood nephrotic syndrome.

Authors:  Sung-Do Kim; Il-Soo Kim; Byung-Cheol Lee; Kang-Duk Choi; Joo-Ho Chung; Chun-Gyoo Ihm; Byoung-Soo Cho
Journal:  Pediatr Nephrol       Date:  2003-02-13       Impact factor: 3.714

3.  Protective role of the apolipoprotein E2 allele in age-related disease traits and survival: evidence from the Long Life Family Study.

Authors:  Alexander M Kulminski; Nalini Raghavachari; Konstantin G Arbeev; Irina Culminskaya; Liubov Arbeeva; Deqing Wu; Svetlana V Ukraintseva; Kaare Christensen; Anatoliy I Yashin
Journal:  Biogerontology       Date:  2016-07-22       Impact factor: 4.277

4.  A Common APOE Polymorphism Is an Independent Risk Factor for Reduced Glomerular Filtration Rate in the Spanish RENASTUR Cohort.

Authors:  Eliecer Coto; Juan Gómez; Beatriz Tavira; Salvador Tranche; Francisco Ortega; María I Rodríguez; Emilio Sánchez; Rafael Marín; Ana I Corao; Jorge Arenas; Victoria Alvarez
Journal:  Cardiorenal Med       Date:  2013-05-16       Impact factor: 2.041

5.  Apolipoprotein E and kidney function in older adults.

Authors:  Rebecca Kurnik Seshasai; Ronit Katz; Ian H de Boer; David Siscovick; Michael G Shlipak; Dena E Rifkin; Mark J Sarnak
Journal:  Clin Nephrol       Date:  2012-09       Impact factor: 0.975

6.  Association of APOE polymorphism with chronic kidney disease in a nationally representative sample: a Third National Health and Nutrition Examination Survey (NHANES III) Genetic Study.

Authors:  Audrey Y Chu; Rulan S Parekh; Brad C Astor; Josef Coresh; Yvette Berthier-Schaad; Michael W Smith; Alan R Shuldiner; Wen Hong L Kao
Journal:  BMC Med Genet       Date:  2009-10-23       Impact factor: 2.103

7.  Apolipoprotein E2 accentuates postprandial inflammation and diet-induced obesity to promote hyperinsulinemia in mice.

Authors:  David G Kuhel; Eddy S Konaniah; Joshua E Basford; Courtney McVey; Colleen T Goodin; Tapan K Chatterjee; Neal L Weintraub; David Y Hui
Journal:  Diabetes       Date:  2012-09-06       Impact factor: 9.461

Review 8.  Apolipoprotein E gene variants on the risk of end stage renal disease.

Authors:  Cheng Xue; Wei Nie; Dan Tang; Lujiang Yi; Changlin Mei
Journal:  PLoS One       Date:  2013-12-13       Impact factor: 3.240

Review 9.  High-Density Lipoproteins and the Kidney.

Authors:  Arianna Strazzella; Alice Ossoli; Laura Calabresi
Journal:  Cells       Date:  2021-03-31       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.